Insmed (INSM)- Has a drug out that’s being reviewed by the FDA Aug 15.
It doesn’t work better than the competition, which is significantly cheaper.
My doctor friend thinks it won’t be approved, but because it’s so far out, I think we can gain on the upswing in the runup to the FDA meeting.
eta: fixed the stock symbol